Orbactiv 01
Orbactiv Injection, Powder, Lyophilized, For Solution
Product Images NDC 70842-140
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Orbactiv (NDC 70842-140). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Melinta Therapeutics, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Orbactiv 02
Orbactiv* (oritavancin) is a medication for intravenous infusion only. It comes in a single-dose vial that contains 400 mg of oitavancin. The recommended dosage is 1,200 mg administered as a single dose by intravenous infusion over three hours. Each vial should be reconstituted with 40 mL of sterile water for injection, and the reconstituted solution should be further diluted in 1,000 mL 5% Dextrose Injection as per the prescribing information before intravenous infusion. The medication should not be diluted with Sodium Chloride Injection. The medication should be stored between 20°C-25°C and excursions are permitted to 15°C-30°C. Each package contains three 400 mg single-dose vials. Orbactiv* is marketed by Melinta Therapeutics, LLC, located in Lincolnshire, IL, USA.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
